ReviewCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2019
Management of ovarian cancer risk in women with
Review in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Reproductive Challenges in Mutated BRCA Gene Carriers: A Narrative Review.Current issues in molecular biology · 2026Review
- Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring.Cancers · 2026Review
- Global epidemiology of ovarian cancer: patterns, trends, and risk factors.Cancer biology & medicine · 2026Review
- Identification and Computational Analysis ofMedical sciences (Basel, Switzerland) · 2025Article
- Redefining Risk, Biomarkers, and Precision Therapy for Hereditary Ovarian Cancer: A Review.ACS omega · 2025Review
- Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with aOncology letters · 2025Article
- A metabolite-based liquid biopsy for detection of ovarian cancer.Biomarker research · 2024Article
- Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.Journal of experimental & clinical cancer research : CR · 2024Review
- Age-specific breast and ovarian cancer risks associated with germlineThe Lancet regional health. Western Pacific · 2024Article
- The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery inCurrent oncology (Toronto, Ont.) · 2023Review
- Computable structured aptamer for targeted treatment of ovarian cancer.Frontiers in genetics · 2023Article
- Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.International journal of environmental research and public health · 2022Review
- Dual BRCA1 and BRCA2 pathogenic variants in an adolescent with syndromic intellectual disability.Clinical case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.